Viking Therapeutics Inc (VKTX)

[DewDiligence]

WSJ take on NVO, LLY et al:

https://www.wsj.com/health/pharma/theres-a-new-obesity-king-ef5a4c8a

“The easier money has already been made,” says [Kevin Gade of Bahl & Gaynor]. “Reaching initial projections of $50 billion in annual sales was doable. But achieving the $150 billion projections some analysts are putting out there will require some gymnastics to make the numbers work.”

Novo’s disappointing [CagriSema] data, and its subsequent market value drop [-21% today], suggests Wall Street doesn’t believe those numbers will work—at least not for Novo. Lilly, however, has a better shot. Yet, as recent events show, the stakes are higher now, and the margin for error is shrinking.